STAT3 and congenital rubella syndrome: Furthermore, the therapeutic efficacy of the STAT3 on-target strategy in reducing uncontrolled inflammation and acute disease becomes the laying of a groundwork for the development of more precise and evidence-based therapies to treat CRS disorders and severe clinical aspects of the ongoing COVID-19 pandemic crisis.